Currently, Kyocera's technology enables aerial images whose focal positions vary by color. In the future, increasing the ...

Multiple clinical data readouts expected in 2026 present opportunity for substantial value creationKOASTAL-2 and -3 on track for consolidated ...

A device smaller than a grain of dust is emerging as a surprisingly powerful candidate to reshape how quantum computers are ...

A device smaller than a grain of dust may help unlock the kind of quantum computers people have only dreamed about. Built on ...

Impressively, the unit registered the lowest frequency loss of any chip to date. Specifically, the engineers noted that the new chip was 15x more stable and 100x more efficient in terms of microwave ...

Aldeyra ’s Reproxalap is the core catalyst. The FDA will make its decision on this asset by March 16, 2026, after a ...

TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads today ...

Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.

A new microchip-sized device could dramatically accelerate the future of quantum computing. It controls laser frequencies ...

This move represented a sharp increase in price on volume nearly 3x the average daily trading volume, indicating robust ...

Edgewise's EDG-7500 showed clinical activity and a favorable safety profile in Phase 2 trial for hypertrophic cardiomyopathy.

Reviva Pharmaceuticals Holdings Inc. may be headed back to the clinic for another phase III study of brilaroxazine in treating schizophrenia. With a successful series of early and mid-stage studies ...